Gensight Biologics SA Stock
€0.28
Your prediction
Gensight Biologics SA Stock
Pros and Cons of Gensight Biologics SA in the next few years
Pros
Cons
Performance of Gensight Biologics SA vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Gensight Biologics SA | 0.530% | -1.563% | -17.105% | -58.613% | -36.005% | -96.351% | -82.325% |
Celsion Corp. | -7.810% | -7.087% | 20.408% | 7.273% | 98.319% | -91.495% | -94.646% |
India Globalization Capital | 3.170% | 8.939% | 13.372% | 28.289% | 48.855% | -67.282% | -66.587% |
Protara Therapeutics Inc. | 0.990% | -1.923% | -5.556% | -15.702% | 20.710% | -71.862% | - |
Comments
News
GenSight Biologics Launches Newsletter for Retail Investors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal